Oncogenic protein provokes cell cycle arrest termed premature senescence. In this process Ras has been known to induce cyclin-dependent kinase inhibitor (CKI) p16 INK4A in primary fibroblasts. Here, we present a novel finding that human chimeric oncoprotein SYT-SSX1 induces CKI p21 WAF1/CIP1 (p21) for suppression of cell growth. In human synovial sarcoma cell lines, the expression levels of p21 were high and the transcriptional activity of the p21 gene promoter was significantly elevated. The transient expression of SYT-SSX1-induced activation of the p21 gene promoter in human diploid fibroblasts. The N-terminus deletion form of SYT-SSX1, which failed to bind to hBRM one of the chromatin remodeling factors, preserved the p21 induction ability. This effect of SYT-SSX1 was similar in extent in both wild-type and p53-deficient HCT116 cell lines. Furthermore, the introduction of mutation in Sp1/Sp3 binding sites of the p21 gene promoter abolished the SYT-SSX1-induced transcriptional activity of its promoter. In SW13 cells, the stable expression of SYT-SSX1 suppressed cell growth in culture. These results suggest that SYT-SSX1 is able to induce p21 in a manner independent on hBRM and p53 but dependent on Sp1/Sp3. Oncogene (2005) 24, 7984-7990.
Introduction
Various cellular stresses and damages including oncogenic signals have been known to induce cell cycle arrest termed premature senescence (Lloyd, 2002) . Cellular senescence was originally described as a state characterized by the cessation of cell division in normal human fibroblasts (Hayflick, 1965) . The shortening of telomeres at a limited number of cell divisions is responsible for such replicative senescence (Bodnar et al., 1998) . Senescent cells have large and flat morphology and exhibited nuclear abnormalities as well as increased senescence-associated b-galactosidase (SA-b-gal) activity (Dimri et al., 1995) .
Oncogenic stimulation induces premature senescence to ensure the damaged cells stop to proliferate. The arrest of the cell cycle in such senescent cells has been shown to be mediated by cyclin-dependent kinase inhibitors (CKIs) such as p16 INK4a (p16) and p21 WAF1/CIP1 (p21) (Hara et al., 1996; Bunz et al., 1998) . The Rasinduced premature senescence in mouse embryonal fibroblasts (MEFs) was shown to be mediated by induction of p16 through the transcription factors Ets1 and Ets2 (Serrano et al., 1997; Ohtani et al., 2001) . Synovial sarcoma is a malignant soft-tissue tumor that develops mostly in the para-articular regions of adolescents and young adults (Weiss and Goldblum, 2001) . It manifest a characteristic chromosomal translocation, t(X;18)(p11.2;q11.2) forming a chimera gene, SYT-SSX1, as the result of fusion between SYT (synovial sarcoma translocation) on chromosome 18 and SSX1 (synovial sarcoma X break point 1) on the X chromosome (Clark et al., 1994; Sandberg and Bridge, 2002) . The wild-type SYT may be involved in chromatin remodeling because of the association of SYT with the chromatin-remodeling factor hBRM (Nagai et al., 2001 ) and with histone acetylase p300 (Eid et al., 2000) . The SSX gene family includes SSX1, SSX2, SSX3, and SSX4, and SSX1 and SSX2 genes have been identified as the major fusion partners of SYT. SSX1 possesses two transcriptional repressor domains, a Kru¨ppel-associated box (KRAB) and an SSX repressor domain (SSXRD) (Crew et al., 1995; Lim et al., 1998) . Although SSX1 as well as SYT have been shown to transactivate the transcriptional activity of Gal4 (Brett et al., 1997) , physiological roles for SSX is still unknown.
In our previous study, the transforming activity of SYT-SSX1 appeared to depend on the type of cells. We could establish SYT-SSX1-expressing cell lines from rat fibroblasts 3Y1 but not from mouse fibroblasts NIH 3T3 (Nagai et al., 2001) . Thus, we hypothesized that SYT-SSX1 might induce cell cycle arrest in certain cell types by the analogy to Ras-induced premature senescence. We now show that p21 expression level is markedly increased in human synovial sarcoma cell lines and that SYT-SSX1 upregulates p21 expression in an hBRM-and p53-independent and Sp1/Sp3-dependent manner.
Results
Expression of p21 in human synovial sarcoma cells and activation of p21 gene promoter by SYT-SSX1 in various cell lines
To analyse the growth inhibitory effect of SYT-SSX1, we examined the protein expression levels of one of the CKIs, p21 and found that the amount of p21 was greatly increased in the human synovial sarcoma cell lines Fuji and SYO-1 compared with that in the other cell lines (Figure 1a) . Then, we analysed the activity of p21 gene promoter in synovial sarcoma cell lines, and the luciferase assay revealed that the p21 promoter activity of Fuji, SYO-1, HS-SY-II, and FU-SY1 cells was greater than that of the other human cancer cell lines such as IMR32, Saos-2, and SW13 cells (Figure 1b) .
To determine whether SYT-SSX1 indeed activates the p21 gene promoter, we transiently transfected cells with a mammalian expression plasmid for SYT-SSX1 in various cells. In human diploid fibroblasts (HDFs) including TIG-1, TIG-3, and MRC5 cells, SYT-SSX1 induced a marked increase in the activity of p21 gene promoter ( Figure 1c) . Expression of SYT-SSX1 also increased the activity of the p21 gene promoter in the human cancer cell lines SW13, Saos-2, and HCT116 ( Figure 1d ). Among rodent cells, the activation of the p21 gene promoter by SYT-SSX1 was apparent in NIH3T3 cells but not in 3Y1 cells or MEFs (Figure 1e ).
It should be note that we analysed the genomic sequences of p21 gene in synovial sarcoma cell lines and no mutation was observed in SYO1 and HS-SY-II (data not shown). In Fuji cells, we found the point mutation at codon 31, AGC to AGA corresponding to the amino acid substitution of Ser to Arg, which has been reported as polymorphism (data not shown).
hBRM is not required for SYT-SSX1-induced activation of p21 gene promoter
To examine the role for hBRM in SYT-SSX1-induced activation of p21 promoter, we utilized SW13 cell line, which lacks hBRM (Dunaief et al., 1994) , and N-terminal deletion mutant of SYT-SSX1-dN43, which does not bind to hBRM (Figure 2a) . By luciferase assay, SYT-SSX1 activated p21 promoter in SW13 cells more than p53 did, and dN43 mutant form of SYT-SSX1 also activated p21 promoter (Figure 2b ). Among several deletion form of SYT-SSX1, SYT-SSX1 mutants that lack either the QPGY domain (dQPGY) or the COOHterminal 60 amino acids (dC128) failed to induce p21 expression (Figure 2b) . By the immunoblot analysis, protein expression of p21 was detectable by wild-type SYT-SSX1 and dN43 mutant in the absence of hBRM in SW13 cells (Figure 2c ). With the coexpression of hBRM, increased amounts of p21 were demonstrated by wild-type SYT-SSX1 but also by dN43, and dN181 mutants (Figure 2c ). As p53 is a well-known inducer for p21 (el-Deiry et al., 1993), we examined the requirement of p53 for SYT-SSX1-induced p21. Transiently expressed SYT-SSX1 clearly activated p21 promoter in p53-deficient (p53 Figure 3) . Activation of the p21 gene promoter in these cells was also induced by the dN43 mutant but was not remarkable by dN181, dQPGY, or dC128 or by SYT or SSX1 alone. Transient transfection of p53 in the p53 À/À cells increased the basal levels of p21 promoter activity but did not substantially alter the effect of SYT-SSX1 (Figure 3) .
To identify the mediator (or mediators) of the activation of the p21 gene promoter by SYT-SSX1, we examined the responsiveness of various p21 promoter mutants to SYT-SSX1 (Figure 4a ). Consistent with the observation that SYT-SSX1 activated p21 gene promoter in p53-deficient cells, SYT-SSX1 activated the mutant 1 and 2 promoters, each of which lacks one of the two p53 binding sites, in SW13 cells (Figure 4a ). SYT-SSX1 also activated deletion forms of the p21 gene promoter present in pGL3b-400 and pGL3b-225, each of which lacks both p53 binding sites. The minimal region of the p21 promoter that responded to SYT-SSX1 was the 60-bp sequence present in pGL3b-60 ( Figure 4a ). The promoter activity of pGL3b-60 is attributable to its interaction with Sp1 or Sp3 (Xiao et al., 1999) . The introduction of a 6-bp deletion in the GC box (Sp1 or Sp3 binding site) of pGL3b-60, yielding pGL3b-60#4, rendered the promoter unresponsive to SYT-SSX1 (Figure 4a ). These results thus suggest that SYT-SSX1 activates the p21 gene promoter by a mechanism that is independent on p53 but dependent on Sp1 or Sp3.
To confirm the results of luciferase assay presented in Figure 4a , we examined the activity of p21 promoter linked to a green fluorescent protein (GFP) reporter gene by using HeLa cells stably expressing SYT-SSX1. By the introduction of pGL3b-60-GFP, the GFP signals were demonstrated in HeLa cells stably expressing SYT-SSX1 ( Figure 4b ). However, with transfection with pGL3b-60#4-GFP, in which the binding site for Sp1 or Sp3 is mutated, no GFP signal was detected in SYT-SSX1-expressing cells (Figure 4b ). 
Inhibition of cell growth of SW13 by SYT-SSX1
We previously showed that hBRM is required for SYT-SSX1-induced transformation (Nagai et al., 2001) . To examine the biological effects of SYT-SSX1-induced p21 expression, we utilized hBRM negative cell line SW13 for excluding the transforming activity of SYT-SSX1. We established SW13 cell lines (SYT-SSX1-1 and SYT-SSX1-2 cells) that stably express SYT-SSX1 (Figure 5a ). SYT-SSX1 was localized to the nucleus of these cells, where it exhibited a speckled distribution pattern (Figure 5b ), consistent with previous observations (dos Santos et al., 1997) . The luciferase activity of the p21 gene promoter pGL3b-4542 was increased in the SW13 cells stably expressing SYT-SSX1 (Figure 5c ), together with the increase of the levels of p21 (Figure 5d ). Consistent with the induction of p21 expression by SYT-SSX1, the growth rates of SYT-SSX-1-1 or SYT-SSX-1-2 cells were suppressed in culture compared with that of parental or vector-transfected SW13 cells (Figure 5e ).
Discussion
Oncogenic stress has been known to arrest cell cycle in primary fibroblasts. In rodent fibroblasts, Ras was known to induce CKI p16 through the transcription factor Ets1 and Ets2 and suppress cell cycle leading to premature senescence. In this study we have found another novel finding that chimeric oncogene SYT-SSX1 induced CKI p21 through the transcription factor Sp1 and Sp3 ( Figure 6 ). By luciferase reporter gene assay, we showed that the activity of the p21 gene promoter was increased in human synovial sarcoma cell lines, whereas that of the p16 gene promoter was not (data not shown). were transiently transfected with the GFP reporter plasmids pGFP-60-GFP or pGFP-60#4-GFP (upper scheme). The pCMV-GFP expression plasmid, in which expression of GFP can be derived by cytomegarovirus immediate-early promoter, was used as a positive control for the transfection. Thirty hours after the transfection, expression of GFP was observed by fluorescence microscopy Induction of p21 by SYT-SSX1 M Tsuda et al SYT-SSX1 was shown to activate the p21 promoter also in HDFs, NIH 3T3 cells but not in 3Y1 cells. This observation might explain why SYT-SSX1 induces transformation in 3Y1 cells, but not in NIH 3T3 cells (Nagai et al., 2001 ). The growth-suppressive effect of SYT-SSX1 may be dominant over the transforming effect in NIH 3T3 cells. By the analogy of Ras-induced p16 expression in which transcription was suppressed by Id1, the inhibitory factor may also function in SYT-SSX-induced p21 expression. As the DNA-binding activity of Sp1 was shown to be inhibited by nuclear extracts of rat fibroblasts (Ammendola et al., 1992) , it is possible that 3Y1 rat fibroblasts express such an inhibitory factor ( Figure 6 ). As the abundance of Sp1 or Sp3 did not correlate with the ability of SYT-SSX1 to activate the p21 gene promoter in various cell lines examined (Supplementary information 1) , we are planning to identify further mechanism of transcriptional regulation of p21 promoter by SYT-SSX1. It should be noteworthy that expression of p21 was properly enhanced by treatment of proteasome inhibitor in synovial sarcoma cells, suggesting that no significant abnormality of protein degradation system causes elevation of p21 in these cells ( Supplementary  Information 2) .
We focused on the role of p53 in p21 expression because synovial sarcoma has been shown to be more aggressive in patients with p53 mutations (Pollock et al., 1996; Schneider-Stock et al., 1999) . However, SYT-SSX1 increased the activity of the p21 gene promoter in p53-deficient HCT116 cells as well as in the wild-type cells. Furthermore, deletion of the two p53 binding sites from the p21 promoter had no effect on the ability of SYT-SSX1 to activate it. Thus, SYT-SSX1-induced p21 through p53-independent mechanism, in spite of abovementioned clinical analysis.
As we have demonstrated that the transforming activity of SYT-SSX1 depends on its association with hBRM (Nagai et al., 2001) , the implication of hBRM in SYT-SSX1-induced p21 expression was also examined. SYT-SSX1 induced p21 in hBRM negative cell line SW13. The coexpression of hBRM and dN43 mutant enhanced transcription of p21 promoter as well as hBRM and wild-type SYT-SSX1 did. Thus, the enhancement of p21 promoter activity by hBRM (Figure 2c ) may not be due to the association of hBRM and SYT-SSX1. Considering the fact that we observed growth suppression of SW13 cells by the stable expression of SYT-SSX1, we conclude that SYT-SSX1 induced p21 expression through hBRM-independent mechanism. As suggested by the mutational analysis, QPGY domain of SYT-SSX1 may function to regulate the transcription of p21 promoter. In addition, the C-terminus of SYT-SSX1 which was reported to bind to histone may also contribute to the transcriptional regulation (Kato et al., 2002) . In Figure 2c , coexpression of hBRM with SYT-SSX1 enhanced the protein levels of Mechanism of the SYT-SSX1-induced growth suppression. SYT-SSX1 provokes transformation through the chromatin remodeling factor hBRM. However, SYT-SSX1 induced p21 in hBRM-independent and Sp1/Sp3-dependent manner. p53 is not involved in this process. By comparison with Ras-induced p16 expression regulated by Ets and Id1, the putative suppressive factor (X) may be present in regulation of Sp1/Sp3 under the control of SYT-SSX1. When cells were exposed by the oncogenic stresses, the balance between growth positive signals such as Ras-induced Erk activation or SYT-SSX1-induced hBRM activation and cell cycle suppressive signals regulated by CKI such as p16 or p21 may determine the phenotype of cells
Induction of p21 by SYT-SSX1 M Tsuda et al p21 probably due to the potential of hBRM as general enhancer for transcription as reported. Given that oncogenic stress induces premature senescence in certain cell types, as exemplified by Rasinduced senescence in MEFs (Serrano et al., 1997) , we examined whether SYT-SSX1 also might trigger premature senescence. However, we did not observe the morphological change and enhancement of SA-b-gal activity in the SYT-SSX1 transfected HDFs. Besides, it should be noted that all four human synovial sarcoma cell lines that we examined exhibited remarkably high levels of SA-b-gal activity (data not shown).
As clinical study showed that synovial sarcoma caused by the SYT-SSX1 oncogene tends to be more aggressive than does that caused by SYT-SSX2 (Kawai et al., 1998) , we, therefore, examined the effect of SYT-SSX2 expression on the activity of the p21 gene promoter. However, SYT-SSX1 and SYT-SSX2 activated the promoter to similar extents (data not shown).
Our study has revealed a growth-suppressive activity of SYT-SSX1 in addition to the transforming activity of this chimeric oncoprotein. The balance of these opposite effect of oncogene may determine the phenotype of the cells. In SW13 cells, it is thought that growth inhibitory effect of SYT-SSX may be dominant more than transforming activity due to the lack of hBRM. The induction of p21 by SYT-SSX1 to induce growth suppression might form the basis of a new approach to the treatment of synovial sarcoma.
Materials and methods

Cells
3Y1 rat fibroblasts (JCRB0734), NIH 3T3 mouse fibroblasts (CRL-1658), SW13 human adrenocortical carcinoma cells (JCRB9069), Saos-2 human osteosarcoma cells, IMR32 human neuroblastoma cells, U251 human glioblastoma cells (JCRB0128), HeLa human cervical carcinoma cells, 293T human embryonic kidney cells, and COS7 simian renal cells (CRL-1651) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). PC12 rat pheochromocytoma cells (CRL-1721) were maintained in DMEM supplemented with 10% FBS and 5% horse serum. HCT116 human colon cancer cells, deficient in p53 were kindly provided by B Vogelstein and maintained in McCoy's 5A medium supplemented with 10% FBS. The HDFs TIG-1 (JCRB0537), TIG-3 (JCRB0510), and MRC5 (JCRB9008) were obtained from the Health Science Research Resources Bank (Japan Health Science Foundation). MEFs were prepared from day-13 mouse embryos. SYO-1 and HS-SYII human synovial sarcoma cells were established by A Kawai (NCC, Tokyo, Japan) and by H Sonobe (Kouchi Medical School, Kouchi, Japan), respectively, and were maintained in DMEM supplemented with 10% FBS. Fuji and FU-SY-1 human synovial sarcoma cells were established by T Nojima (Kanazawa Medical College, Kanazawa, Japan) and by J Nishio (Nishio et al., 2002) , respectively, and were maintained in RPMI supplemented with 10% FBS or in type I collagen-coated dishes containing DMEM-Ham's F12 medium supplemented with 10% FBS. All cells were cultured at 371C under a humidified atmosphere containing 5% CO 2 .
Antibodies
Rabbit polyclonal antibodies to SSX1 were kindly provided by H Hiraga. Mouse monoclonal antibodies to p21 WAF1/CIP1 (Ab-1) were obtained from Oncogene (Cambridge, MA, USA), those to p53 were from DAKO (Tokyo, Japan) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), those to Flag (M2) were from Sigma (St Louis, MO, USA), and those to HA (12CA5) were from Roche (Indianapolis, IN, USA).
Plasmids
The luciferase reporter plasmid containing the full-length promoter (nucleotides À4542 to þ 132, relative to the transcriptional start site) of the mouse p21 WAF1/CIP1 gene, pGL3b-4542, and its deletion mutants pGL3b-400, pGL3b-225, pGL3b-60, and pGL3b-60#4 were described previously (Xiao et al., 1999) . The pGL3b-4542 mutants lacking either of the two p53 binding sites, mutant1 (lacking nucleotides À2815 to À2796) and mutant 2 (lacking nucleotides À1923 to À1904), were also described previously (Xiao et al., 1997) . The mammalian expression plasmids pCXN2-SYT, pCXN2-SSX1, and pCXN2-SYT-SSX1 as well as the corresponding vectors for the SYT-SSX1 deletion mutants dN181 and dQPGY were described previously (Nagai et al., 2001) . The pCXN2 vectors for the dN43 and dC128 mutants of SYT-SSX1, which lack the NH 2 -terminal 43 amino acids and the COOH-terminal 60 amino acids of SYT-SSX1, respectively, were constructed. The vector pcDNA3-HA-hBRM was described previously (Nagai et al., 2001) . The vector for p53 was kindly provided by M Tada. For construction of pGL3b-60-GFP and pGL3b-60#4-GFP, the cDNA for luciferase was excised from pGL3b-60 and pGL3b-60#4 by digestion with NcoI and XbaI and was replaced by the cDNA for GFP excised from pEGFP (Clontech, Palo Alto, CA) by digestion with the same two endonucleases.
Luciferase reporter assay of p21 promoter activity Cells were plated on 24-well plates at a density of 2 Â 10 5 per well and were transfected, with the use of the Fugene6 reagent (Roche, Indianapolis, IN, USA), with the luciferase reporter plasmid (1 mg per well), with the thymidine kinase promoterdriven Renilla luciferase plasmid pRL-TK (20 ng per well) (Promega, Madison, WI, USA), and with various expression plasmids (1 mg per well). After 2 days, the cells were lysed and luciferase activity was measured with a Dual Luciferase Assay Kit (Promega). The activity of firefly luciferase was normalized by that of Renilla luciferase.
Immunoblot analysis
Cells were lysed for 10 min on ice in a solution containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride (Sigma), and 1 mM Na 3 VO 4 . The lysates were centrifuged at 20 000 g for 10 min at 41C, and the resulting supernatants were subjected to SDSpolyacrylamide gel electrophoresis. The separated proteins were transferred to a polyvinylidene difluoride membrane (Immobilon; Millipore, Billerica, MA, USA) and subjected to immunoblot analysis with the indicated antibodies. Immune complexes were detected with ECL reagents (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and quantified with a Lumino Image Analyzer (LAS1000; Fuji Film, Tokyo, Japan).
Establishment of stable cell lines
To establish HeLa and SW13 cell lines that stably express SYT-SSX1, we transfected the parental cells with pCXN2-Flag-SYT-SSX1. The cells were cultured in the presence of Geneticin (0.4 mg/ml) (Invitrogen, Carlsbad, CA, USA) beginning 2 days after transfection and drug-resistant colonies were subsequently isolated.
Laser-scanning confocal microscopy
To examine the subcellular localization of SYT-SSX1 in stably transfected HeLa or SW13 cells, we fixed the cells with 3% paraformaldehyde for 15 min at room temperature, permeabilized them for 4 min with 0.1% Triton X-100 at room temperature, and then fixed them again with 70% methanol for 5 min at À201C. The cells were treated with 1% goat serum to block nonspecific binding of antibodies and were then incubated first overnight at 41C with antibodies to Flag tag (1 : 1000 dilution) or SSX1 (1 : 500 dilution) and then for 1 h at room temperature in the dark with Alexa 488-conjugated goat antibodies to rabbit immunoglobulin (1 : 400 dilution; Molecular Probes, Eugene, OR, USA). The cells were observed with a laser-scanning confocal microscope (FV-300; Olympus, Tokyo, Japan).
